Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
2 June 2020Americas

PTAB to review Minnesota patent after Gilead petition

Gilead Sciences has persuaded the US Patent Trial and Appeal Board (PTAB) to review an antiviral patent owned by the  University of Minnesota (UM).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead expands oncology business with Pionyr deal
25 June 2020   Gilead Sciences has begun a potential takeover of Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.
Americas
No fees award for PTAB proceedings, rules Fed Circuit
5 June 2020   The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.
Big Pharma
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24 October 2019   The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Americas
Gilead expands oncology business with Pionyr deal
25 June 2020   Gilead Sciences has begun a potential takeover of Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.
Americas
No fees award for PTAB proceedings, rules Fed Circuit
5 June 2020   The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.
Big Pharma
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24 October 2019   The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.

More on this story

Americas
Gilead expands oncology business with Pionyr deal
25 June 2020   Gilead Sciences has begun a potential takeover of Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.
Americas
No fees award for PTAB proceedings, rules Fed Circuit
5 June 2020   The US Court of Appeals for the Federal Circuit has said it cannot award attorneys’ fees for proceedings before the US Patent Trial and Appeal Board.
Big Pharma
Brazil accuses Gilead over 1,421.5% price hike of hep C drug
24 October 2019   The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.

More features

AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory